The latest announcement is out from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ).
JCR Pharmaceuticals announced the presentation of promising data from its investigational therapies for lysosomal storage disorders at the WORLDSymposium™ 2025. The presentations highlighted the potential of their J-Brain Cargo® technology, with evidence showing that JR-141 has long-term safety and efficacy for MPS II, while JR-479 demonstrated positive non-clinical results for GM2 gangliosidoses. These advancements could strengthen JCR’s position in the market and potentially offer new treatment options for these challenging conditions.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a company based in Hyogo, Japan, focusing on developing therapies for lysosomal storage disorders. They leverage their proprietary J-Brain Cargo® technology to deliver biotherapeutics across the blood-brain barrier, with products like IZCARGO® already approved for mucopolysaccharidosis type II in Japan.
YTD Price Performance: -18.45%
Average Trading Volume: 379,991
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen61.5B
For a thorough assessment of 4552 stock, go to TipRanks’ Stock Analysis page.